L-ARGININE SUPPLEMENTATION IMPROVES POST-EXERCISE HYPOTENSION IN ELDERLY WOMEN

ABSTRACT

Introduction: L-Arginine supplementation increases plasma levels of nitric oxide (NO) metabolites, an important mediator of peripheral dilatation. Therefore, L-Arginine supplementation can improve the duration and magnitude of post-exercise hypotension. Objectives: This study investigated the effects of L-Arginine supplementation on post-exercise hypotension, femoral artery area and heart rate variability in elderly women. Methods: Twenty prehypertensive and hypertensive adult female participants were divided (in a random and balanced manner) into two groups (placebo and L-arginine). The participants ingested eight grams of inert substance (placebo group) or eight grams of L-Arginine (L-arginine group), dissolved in water, 90 min prior to the experimental session. The experimental session consisted of an isokinetic maximal strength test. Blood pressure was measured using an oscillometric device (Omron MX3 Plus, Bannockburn, US) every 10 minutes for 60 minutes after the experimental session. Femoral artery area (ultrasound) and heart rate variability were also analyzed. Data underwent repeated measures (ANOVA) analysis and respective assumptions. Results: L-Arginine supplementation associated with exercise produced a significant decrease in systolic blood pressure [placebo vs L-Arginine] (p <0.05) at the “half-life” time point (90 minutes after supplementation) (141±12 vs 130±11 mmHg) and 40 min. (146±13 vs 127±13 mmHg), 50 min. (145±20 vs 127±15 mmHg) and 60 min. (147±19 vs 129±14mmHg) post-exercise. No significant differences were identified in femoral artery area and heart rate variability. Conclusion: Acute L-Arginine supplementation can increase post-exercise hypotension effects in elderly women. Additionally, acute L-Arginine supplementation is not related to either femoral artery area or heart rate variability responses. Level of evidence I; Randomized clinical trial.

Keywords: Arterial pressure; Vasodilation; Arginine.
INTRODUCTION
The social conditions and technological advances evidenced in the last century allowed a significant improvement in the health conditions of the population. Consequently, there has been a significant increase in life expectancy and an increase in the elderly population. In this scenario, infect-contagious diseases, which were responsible for high mortality rates, are no longer prevalent. On the other hand, there is a significant prevalence/incidence increase of chronic-degenerative diseases due to modern lifestyle characteristic. Among chronic-degenerative diseases, systemic arterial hypertension and, consequently, cardiovascular diseases.

Physical activity practice is an important non-pharmacological resource for maintaining blood pressure control. Several studies have demonstrated that regular exercise promotes chronic blood pressure (BP) reduction, through aerobic or resistance exercise. In addition, there is still an acute reduction phenomenon called post-exercise hypotension (PEH), identified in both normotensive and hypertensive individuals.

Different regulatory mechanisms can be related to BP changes. In general, changes in cardiac contractility, microvessel density, arterial and venous blood volume, heart thickness and morphology can modulate BP. Thus, the autonomic nervous system also plays an important role in cardiovascular control, acting on heart rate, peripheral vascular resistance and consequently cardiac output and BP.

The nitric oxide (NO) synthesis is another important process that must be considered in relation to BP. NO plays an important role in increasing blood flow, vasodilation, and blood perfusion. NO can be produced in the mammalian organism or by the endogenous substrates such as L-Arginine (ARG) and L-Citrulline. Studies have shown that during the aging process there is a decrease in NO production and ARG (essential amino acid). This reduction is intrinsically related to physical exercise intolerance and cardiovascular risk factors. Considering the importance of NO as a vasodilator, several pharmacological and nutritional therapies have emerged recently.

Since ARG is the main endogenous substrate related to NO synthesis, the ARG supplementation may play an important vasodilatory role, maximizing the already known post-exercise hypotensive effect, becoming another important tool for the treatment and prevention of hypertension. In this sense, the objective of the present study was to verify the impact of a single aerobic physical exercise session associated with ARG supplementation on BP, femoral artery area and heart rate variability (HRV) in elderly women.

METHODS
Participants
After the sample size calculation (see statistical analysis), 20 physically active elderly women (65-80 years old), who voluntarily participated in extension projects (general physical activities [functional exercises and stretching] offered to the community), were invited to compose the present investigation. The inclusion criteria were: (1) nonsmoker, (2) health musculoskeletal condition, (3) have not to use drugs that potentiate or block muscle action, (4) have not to use medicines that increase blood flow, (5) have no surgeries at least six months, (6) have not used ergogenic supplements for at least six months, (7) have no disease or cardiac complication in the last three years, and (8) medical approval for physical exercise practice. All participants were previously informed about the research objectives and procedures. They signed a free and informed consent form approved by the Research Ethics Committee (protocol no. 28443714.0.0000.0108). All procedures were carried out in accordance with Helsinki Declare (1964).

Experimental Design
The present study employed a randomized, double-blind experimental design with placebo group. Initially, all subjects were submitted to a quadriceps muscle isokinetic strength test familiarization. All participants received instructions related to exercise technique and instruments. This procedure was adopted to avoid potential learning effects and guarantee data reliability. Participants were divided randomly (using a random number table) into two groups (N = 10 per group): Placebo (PLA) and ARG (ARG). The participants were submitted to femoral artery doppler ultrasonography (performed by a specialized physician), into three moments: before ARG supplementation (moment 10 minutes [min]), after ARG supplementation (80 min.), and immediately after performing the isokinetic force test of the quadriceps muscle. Initially, participants were instructed to remain at rest for 30 min, they were supplemented with ARG or placebo (8g in a single dose) and kept seated at rest for 80 min. After this, the participants were submitted to ultrasound examination and isokinetic force test. HRV was continuously monitored. BP was monitored every 10 min intervals before (10, 20 and 30 min) and after (40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170,180 min.) supplementation.

Familiarization Protocol
To avoid potential learning effects and to ensure the reliability, all participants were submitted to a familiarization session to receive technique instructions related to isokinetic force test. Two familiarization
training was carried out separated by at least 48 hours. This design was used to minimize the previous fatigue effects on strength tests and to guarantee maximum effort in each test. Each test was run three times during the familiarization phase. A 10 min recovery period was allowed between trials. During all tests, the subjects were continuously monitored and verbally encouraged.

**Anthropometry**

Anthropometric data were collected before the experimental session. The body mass was evaluated with an electronic scale (Plenna Acqua - São Paulo - Brazil). The portable wooden stadiometer was used to stature measures.

**Arginine supplementation**

Subjects were supplemented with ARG (Sigma Aldrich®) or placebo (inert substance), in the same format. ARG was administered after 30 min (8g – single dose) by the solution containing 300 ml of H₂O. The tests were started at 90 min after supplementation (during half-life), considering ARG pharmacokinetic properties.

**Blood flow measurement**

All participants were submitted to a Doppler ultrasonography (System FiVe; GE Medical Systems), performed by a specialized physician. Longitudinal femoral artery images were obtained by a linear matrix (10-MHz) pulse doppler ultrasound probe.

**Isokinetic Strength**

After 80 min of supplementation, all participants underwent to an isokinetic evaluation (knee extensor and flexor muscles) of the dominant limb by the isokinetic dynamometer (Biodex Medical Systems - 3 Isokinetic Dynamometer, Long Island, NY). The participants were positioned on the equipment according to the manufacturer recommendations. The subjects were instructed to perform three sets (10 repetitions; 60°/s [1.05 rad/s-1]), applying recovery time (1 min) between the series. The movement angle was set at 90°. The test was performed after specific warming (eight repetitions - 60%/s) in which participants were instructed to do not perform the maximum effort. The dynamometer axis rotation was aligned to the femoral epicondyle, and the resistance load was allocated two centimeters above the internal malleolus. Possible errors induced by gravity were corrected based on the lower limb weight at 90° and calculated by the equipment software. The subjects were continuously monitored and verbally encouraged by the evaluators. It was not allowed visual feedback.

**Blood Pressure Measures**

Resting BP was measured (every 10 min) by a pre-validated automated monitor (Omron MX3 Plus, Bannockburn, USA12). The subjects adopted the sitting position and the measurement was performed in the left arm, following the American Heart Association recommendations.

**Heart rate variability measurements**

HRV was monitored throughout the experimental session with a previously validated heart rate monitor (Polar - RS800CX, Kempele, Finland)14. The R-R interval ranges recorded on the equipment were transferred to a computer using Polar Precision Performance software (release 3.00, Kempele, Finland). The Fourier transform was used to quantify the low physiological phenomenon. The time differences between adjacent R-Rs) and pNN50 (percentage of adjacent pairs). The systolic BP values were significantly different at the “half-life” (90 min after supplementation) (141 ± 12 vs. 130 ± 11 mmHg) and at 40 min. (146 ± 13 vs. 127 ± 13 mmHg), 50 min. (145 ± 20 vs 127 ± 15 mmHg) and 60 min. (147 ± 19 vs 129 ± 14 mmHg) post-exercise (PLA vs ARG, respectively). Systolic BP remained higher at 10, 20, 30, and 40 min post-exercise for PLA and at 10 and 20 min for ARG compared to rest. There were no diastolic BP differences.

Figure 2 presents femoral artery area results for “pre”, “half-life” (90 min after supplementation) and “post”. No statistically significant differences were identified.

Figures 3 and 4 present the time (figure 3) and frequency (Figure 4) HRV domains indicators. No statistically significant differences were identified.

**RESULTS**

The general characteristics (age, body mass, height, body mass index, heart rate, systolic/diastolic BP and femoral artery area) are presented in Table 1. There were no baseline significant differences (>0.05) between PLA and ARG.

The systolic BP values were significantly different at the “half-life” (90 min after supplementation) (141 ± 12 vs. 130 ± 11 mmHg) and at 40 min. (146 ± 13 vs. 127 ± 13 mmHg), 50 min. (145 ± 20 vs 127 ± 15 mmHg) and 60 min. (147 ± 19 vs 129 ± 14 mmHg) post-exercise (PLA vs ARG, respectively). Systolic BP remained higher at 10, 20, 30, and 40 min post-exercise for PLA and at 10 and 20 min for ARG compared to rest. There were no diastolic BP differences (Figure 1).

Table 1. General characteristics of the sample.

<table>
<thead>
<tr>
<th>Age (years)</th>
<th>Arg (N = 10)</th>
<th>PLA (N = 10)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Body mass (kg)</td>
<td>62.9 ± 3.3</td>
<td>60.4 ± 2.1</td>
<td>0.538</td>
</tr>
<tr>
<td>Height (cm)</td>
<td>153.2 ± 2.3</td>
<td>152.2 ± 1.1</td>
<td>0.699</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>27.1 ± 1.0</td>
<td>26.1 ± 0.7</td>
<td>0.620</td>
</tr>
<tr>
<td>HR (bpm)</td>
<td>76.5 ± 3.5</td>
<td>70.3 ± 2.8</td>
<td>0.287</td>
</tr>
<tr>
<td>Systolic BP (mmHg)</td>
<td>121.5 ± 60</td>
<td>124.3 ± 55</td>
<td>0.123</td>
</tr>
<tr>
<td>Diastolic BP (mmHg)</td>
<td>73.8 ± 1.7</td>
<td>75.8 ± 2.9</td>
<td>0.793</td>
</tr>
<tr>
<td>Femoral artery area (cm²)</td>
<td>0.45 ± 0.03</td>
<td>0.41 ± 0.02</td>
<td>0.327</td>
</tr>
</tbody>
</table>

**DISCUSSION**

To the best of our knowledge, this is the first randomized, double-blind, placebo-controlled study that examined the acute effects of oral ARG supplementation on post-exercise pressure and autonomic responses. It is worth mentioning that PEH is considered an important physiological phenomenon18, and may play a greater role in hypertension.
management since previous studies have shown that PEH magnitude is correlated with chronic BP reductions¹⁹.

It is important to consider that ARG is the main amino acid related to the NO synthesis¹¹, consequently, ARG supplementation may play an important vasodilatory role, although arginine is directly involved in protein synthesis, ureagenesis, agmatine, creatine, polyamines, and proline productions²⁰.

Data from experimental studies suggest that after oral administration, ARG is extensively metabolized by arginase in the intestine and liver, limiting their bioavailability as a NOS substrate and subsequent vasodilator function effects²¹. Boger et al.²² conducted an experimental study using a stable ARG isotope labeled and were able to show that only about 1% of the ARG dose was being used as a nitric oxide synthase (NOS) substrate.

Thus, a high amino acid (8g) supplementation dose is justified in the experimental protocol, trying to ensure that even a small part of the supplement is used as a NOS substrate. This ARG dose has been previously used to promote vasodilator effect in elderly subjects²³. According to Böger²⁴, single doses of 3 to 8 g of ARG appear to be safe and rarely cause adverse events. On the other hand, single doses greater than 9 g appear to be associated with gastrointestinal discomfort and nausea²⁵.
The hypothesis of the present study was that ARG supplementation would maximize the PEH, characterized by the acute BP reduction after a single physical exercise or physical activity session. In turn, the results demonstrated that systolic BP remained lower post 40 min in the ARG supplemented group compared to placebo. This result agree with the initial hypothesis since the ARG supplementation can increase the NO production and consequently peripheral vasodilation.

On the other hand, no significant effects on diastolic BP were identified in the present investigation. Studies investigating PHE has shown smaller diastolic BP variations, several investigations demonstrate PHE only for systolic BP in hypertensive patients.

Another variable analyzed in the present investigation was the femoral artery area. Considering that ARG is directly associated with NO synthesis, we expected the occurrence of vasodilation. However, this increase in the femoral artery area was not confirmed, contradicting the initial hypothesis. On the other hand, the vasodilation in large arteries may not occur systematically, since ARG supplementation may increase blood perfusion (reducing pressure) due to blood flow increase in arterioles and capillaries. The role of microcirculation on systemic vascular resistance is about 70% of the pressure gradient between arteries and veins. The large arteries have architecture adapted to the shock absorption and blood volume accommodation every systole since the capillaries arranged in a single layer of endothelial cells lining the basement membrane cannot receive blood at systemic pressures at the risk of losing structural integrity. The required mechanical damping of the pulse wave is promoted by arterioles equipped with one or two layers of smooth muscle cells in continuous tone. This fact suggests that arterioles were more affected by NO than great vessels.

To identify effects related to the neuro-autonomic mechanism, HRV was investigated in different time/frequency domain components. In this sense, there was no difference in any of the evaluated components, suggesting that PHE identified is not strongly associated with the central adjustments. Since HRV is an indirect autonomic nervous system measure, it was expected no significant changes in the HRV components, considering that HPE mechanisms were more strongly associated with the peripheral adjustments.

It is recommended that future studies add bioavailability markers of nitric oxide measurements, such as nitrite and nitrate. Additionally, evaluation of other important mechanisms such as peripheral vascular resistance and cardiac output may help in understand the ARG body reaction. Finally, future research about ARG supplementation impact on PEH should be performed manipulating different exercise conditions, since exercise variables can change PEH.

CONCLUSION
ARG supplementation may contribute to BP reduction after a single exercise session in hypertensive patients. In addition, ARG supplementation does not appear to promote femoral artery vasodilation and autonomic nervous system changes.

All authors declare no potential conflict of interest related to this article

AUTHORS’ CONTRIBUTIONS: Each author made significant individual contributions to this manuscript. JC (0000-0001-5397-5694)*: design, writing of the article, data interpretation, and review; DMZ (0000-0003-3444-4323)*: writing, critical review, and intellectual concept; DME (0000-0001-5382-8360)*: writing and critical review; KG (0000-0002-8286-6072)*: writing and critical review; APA (0000-0003-3337-2444)* design and critical review. ORCID (Open Researcher and Contributor ID).

REFERENCES